Date of Deposit: March 28, 2005

Attorney Docket No. VPI/03-103 US IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ION NO.: 10/800,022 CONFIRMATION NO.: 6802 FILING DATE: MARCH 12, 2004 **EXAMINER:** NOT YET ASSIGNED **GROUP ART UNIT:** 1614 APPLICANTS: VANGOOR, ET AL. For: MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS March 28, 2005 Cambridge, Massachusetts Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the (a) accompanying Form 1449/PTO be considered and made of record in the above-identified patent application. X Copy(ies) of references Citation No(s). **B1-B4 and C1-C3** is/are attached. Copy(ies) of references Citation No(s). was/were filed in application U.S. Application No(s). filed , from which this application claims priority under 35 U.S.C. § 120.). X A copy of the International Search Report received in the corresponding PCT Application No. PCT/US2004/007492 is attached herewith. X **(b)** No fee is believed due because: The Information Disclosure Statement is being filed within three (3) months of the filing date of the application. The Information Disclosure Statement is being concurrently filed with the above-identified application. The Information Disclosure Statement is being concurrently filed

with a Request for Continued Examination (RCE).

mailing of a first Office Action on the merits.

The Information Disclosure Statement is being filed prior to the

 \bowtie

10/800,022 **APPLICATION NO.:** (c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725. (d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and The Director is hereby authorized to charge \$180.00 to Deposit

APPLICANTS:

VANGOOR, ET AL.

Account No. 50-0725.

APPLICANTS:

VANGOOR, ET AL.

APPLICATION NO.:

10/800,022

 \boxtimes

The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,

Nandakumar Govindaswamy

Reg. No. 56,285

Attorney for Applicants

Vertex Pharmaceuticals Incorporated c/o

130 Waverly Street

Cambridge, Massachusetts 02139

Tel: (617) 444-6619/6100

Fax: (617) 444-6483

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Mail Stop: Amendment, P.O. Box 1450, Alexandria, VA 22313-1450 on _



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/800,022		
Filing Date	March 12, 2004		
First Named Inventor	Frederick F. VanGoor		
Group Art Unit	1614		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	VPI/03-103 US		

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
						١,	

Exam Initials	Cite No.			Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
·	B1	wo	00/07996	Chiron Corporation	17 February 2000		
	B2	wo	03/084544	CV Therapeutics, Inc.	16 October 2003		
	В3	DE	41 26 543	Chem. & Pharm. Patent Hold Ltd.	11 February 1993		
	B4	FR	2.104.932	Ferlux	28 April 1972		

OTHER NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
	CI	Nargund, et al., "Synthesis and Anti-inflammatory Activity of Fluorinated Phenyl Styryl Ketones and N-Phenyl-5-substituted Aryl-3-p-(fluorophenyl) Pyrazolins and Pyrazoles", Journal of Pharm. Sciences, Am. Pharm. Association, Vol 81, No. 9, Pages 892-894, Sept. 1992.				
	C2	Nair, et al. "Synthesis & Reactions of 1-(2-Furyl)-3-(substituted-2-hydroxyphenyl)propanediones", Indian J. Chem., Vol. 21, Pages 573-574, 1982				
	C3	Database Chemcats, Zelinski Inst. Of Organic Chemistry, Moscow, XP-002288253, 2003				
	1					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application,					
U.S.S.N, filed	, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,				
continuation-in-part, and divisional applicati	ions).				

Examiner Signature	Date Considered	
	i	1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.